Rapt Therapeutics Acquisition by GSK: A Strategic Move in Immunologic Therapies

Core Viewpoint - Rapt Therapeutics is making headlines due to its acquisition by GSK, which values the deal at approximately $2.2 billion, despite a recent downgrade in its stock rating from Guggenheim [1][2]. Group 1: Acquisition Details - GSK is acquiring Rapt Therapeutics for $58.00 per share, which represents a significant premium and values the total deal at around $2.2 billion [1][2]. - The acquisition involves an upfront investment of $1.9 billion net of cash acquired, allowing GSK to access RAPT's late-stage food allergy treatment, ozureprubart [2]. Group 2: Product Information - Ozureprubart is a long-acting anti-IgE monoclonal antibody currently in phase 2b clinical development, aimed at providing prophylactic protection against food allergens [2]. - This innovative drug targets IgE, a validated target in severe food allergies, and promises a more convenient treatment option compared to existing therapies that require frequent injections [2]. Group 3: Market Reaction and Legal Investigation - Following the acquisition announcement, RAPT's stock surged by 64%, reaching a new 52-week high of $57.61, with a market capitalization of approximately $951.3 million [1][3]. - Halper Sadeh LLC is investigating the fairness of the sale to ensure it aligns with the best interests of RAPT shareholders and whether the board of directors has fulfilled its responsibilities [3].